Hecht Beth 4

What Happened

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), sold 16,667 shares on 2026-05-01. The weighted-average price was $6.23 per share, resulting in proceeds of approximately $103,805. This was a sale (code S), not a purchase.

Key Details

• Transaction date: 2026-05-01.
• Price: weighted average $6.23; individual sales ranged from $6.10 to $6.32 (report notes multiple transactions).
• Shares sold: 16,667; proceeds ≈ $103,805.
• Shares owned after transaction: not disclosed in the information provided in this summary.
• Footnotes: Transaction executed under a Rule 10b5-1 trading plan (prearranged plan). The filer can provide a breakdown of shares sold at each price within the reported range on request.
• Filing timeliness: Report filed same day (no late-filing indication in this record).

Context

• Sales made pursuant to a 10b5-1 plan are typically pre-scheduled and can be routine; they do not necessarily reflect the insider’s current view of the company’s prospects. For retail investors, purchases usually carry more direct informational value than routine insider sales.